INDV Stock - Indivior PLC
Unlock GoAI Insights for INDV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.19B | $1.09B | $901.00M | $791.00M | $647.00M |
| Gross Profit | $957.00M | $919.00M | $750.00M | $664.00M | $550.00M |
| Gross Margin | 80.6% | 84.1% | 83.2% | 83.9% | 85.0% |
| Operating Income | $32.00M | $-156,000,000 | $-81,000,000 | $213.00M | $-156,000,000 |
| Net Income | $2.00M | $-129,000,000 | $-44,000,000 | $205.00M | $-148,000,000 |
| Net Margin | 0.2% | -11.8% | -4.9% | 25.9% | -22.9% |
| EPS | $0.02 | $0.01 | $-0.37 | $1.38 | $-1.08 |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 6th 2025 | H.C. Wainwright | Initiation | Buy | $27 |
| July 22nd 2025 | Jefferies | Resumed | Buy | $20 |
| January 28th 2025 | Rodman & Renshaw | Initiation | Buy | $16 |
| July 23rd 2024 | Piper Sandler | Initiation | Overweight | $22 |
| April 3rd 2024 | Craig Hallum | Initiation | Buy | $37 |
| July 13th 2023 | Northland Capital | Initiation | Outperform | $35 |
Earnings History & Surprises
INDVEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $0.65 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.38 | $0.72 | +89.5% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.26 | $0.51 | +96.2% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $0.22 | $0.41 | +86.4% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $0.32 | $0.32 | 0.0% | = MET |
Q4 2024 | Oct 24, 2024 | $0.31 | $0.54 | +74.2% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $0.40 | $0.44 | +10.0% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $0.42 | $0.37 | -11.9% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $0.28 | $0.43 | +53.6% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $0.30 | $0.34 | +13.3% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.22 | $0.39 | +77.3% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | — | $0.40 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-1.38 | — | — |
Q3 2022 | Sep 29, 2022 | — | $0.27 | — | — |
Q2 2022 | Jun 29, 2022 | — | $0.33 | — | — |
Q1 2022 | Mar 30, 2022 | — | $0.27 | — | — |
Q4 2021 | Dec 30, 2021 | — | $0.25 | — | — |
Latest News
Indivior Says Data Published In 'JAMA Network Open' Shows SUBLOCADE 100mg And 300mg Improve Opioid Abstinence And Were Well-Tolerated With No New Safety Signals Identified
📈 PositiveIndivior shares are trading higher after the company was added to the S&P SmallCap 600.
📈 PositivePrimoris Services, Casella Waste Systems, Indivior, Hawaiian Electric, LKQ, Solstice Advanced Materials, Mohawk Industries, Under Armour, Power Integrations, Perrigo, Iridium Communications, Marriott Vacations Worldwide And Insperity Added To S&P SmallCap 600
📈 PositiveIndivior Concludes Legacy U.S. Department Of Justice Matter By Paying $295M
📉 NegativeWatching Indivior; Shares Move Higher, Hearing Popular Newsletter Service Picks Stock
📈 PositiveIndivior Data Presented At Academy Of Managed Care Pharmacy Demonstrates Potential Of SUBLOCADE To Treat Opioid Use Disorder
📈 PositivePiper Sandler Reiterates Overweight on Indivior, Raises Price Target to $41
📈 PositiveHC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $35
📈 PositiveIndivior shares are trading higher after the company reported Q3 results above estimates and raised its FY2025 sales guidance.
📈 PositiveIndivior Raises FY2025 Sales Guidance from $1.030B-$1.080B to $1.180B-$1.220B vs $1.088B Est
📈 PositiveIndivior Q3 Adj. EPS $0.72 Beats $0.41 Estimate, Sales $314.000M Beat $261.917M Estimate
📈 PositiveIndivior Reports Rapid Induction With SUBLOCADE In Individuals Who Met Criteria For Moderate-To-Severe Opioid Use Disorder
📈 PositiveCraig-Hallum Maintains Buy on Indivior, Raises Price Target to $34
📈 PositiveFrequently Asked Questions about INDV
What is INDV's current stock price?
What is the analyst price target for INDV?
What sector is Indivior PLC in?
What is INDV's market cap?
Does INDV pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INDV for comparison